Interpace Biosciences engages in oncology by providing services from early diagnosis and prognostic planning to targeted therapeutic applications through its clinical and pharma services. Co.'s commercialized molecular diagnostic tests include: PancraGEN®, which is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians assess risk of pancreaticobiliary cancers using its PathFinderTG® platform; and ThyGeNEXT®, which is an oncogenic mutation panel that helps identify malignant thyroid nodules. Through its pharma services, Co. provides ancillary services, including: biorepository, clinical trial logistics, clinical trial design, and bioinformatics analysis. The IDXG average annual return 10 years is shown above.
The Average Annual Return on the IDXG average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether IDXG average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IDXG average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|